CD8A and neoplasm: While STINGa monotherapy did not modulate CD8 T cell tumor infiltration nor the proportion of HPV-specific, Z13Mad25Anaxa–STINGa combination significantly increased both CD8 T cell infiltration and HPV-specific proportion.